Do we need more drugs for chronic myeloid leukemia?
Identifieur interne : 000F61 ( Main/Exploration ); précédent : 000F60; suivant : 000F62Do we need more drugs for chronic myeloid leukemia?
Auteurs : Tessa L. Holyoake [Royaume-Uni] ; G. Vignir Helgason [Royaume-Uni]Source :
- Immunological Reviews [ 0105-2896 ] ; 2015-01.
Abstract
The introduction of protein tyrosine kinase inhibitors (TKIs) in 1998 transformed the management of chronic myeloid leukemia (CML), leading to significantly reduced mortality and improved 5 year survival rates. However, the CML community is faced with several clinical issues that need to be addressed. Ten to 15% of CML patients are diagnosed in advanced phase, and small numbers of chronic phase (CP) cases experience disease progression each year during treatment. For these patients, TKIs induce only transient responses and alternative treatment strategies are urgently required. Depending on choice of first line TKI, approximately 30% of CML CP cases show suboptimal responses, due to a combination of poor compliance, drug intolerance, and drug resistance, with approximately 50% of TKI‐resistance caused by kinase domain mutations and the remainder due to unknown mechanisms. Finally, the chance of successful treatment discontinuation is on the order of only 10–20% related to disease persistence. Disease persistence is a poorly understood phenomenon; all CML patients have functional Philadelphia positive (Ph+) stem and progenitor cells in their bone marrows and continue to express BCR‐ABL1 by DNA PCR, even when in very deep remission and following treatment discontinuation. What controls the maintenance of these persisting cells, whether it is necessary to fully eradicate the malignant clone to achieve cure, and how that might be approached therapeutically are open questions.
Url:
DOI: 10.1111/imr.12234
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000230
- to stream Istex, to step Curation: 000230
- to stream Istex, to step Checkpoint: 000106
- to stream Main, to step Merge: 000F62
- to stream Main, to step Curation: 000F61
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Do we need more drugs for chronic myeloid leukemia?</title><author><name sortKey="Holyoake, Tessa L" sort="Holyoake, Tessa L" uniqKey="Holyoake T" first="Tessa L." last="Holyoake">Tessa L. Holyoake</name></author><author><name sortKey="Helgason, G Vignir" sort="Helgason, G Vignir" uniqKey="Helgason G" first="G. Vignir" last="Helgason">G. Vignir Helgason</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8FBAE5AFBB10757C28A4B796A960B9E16477F9E4</idno><date when="2015" year="2015">2015</date><idno type="doi">10.1111/imr.12234</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-NC8TXPH4-P/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000230</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000230</idno><idno type="wicri:Area/Istex/Curation">000230</idno><idno type="wicri:Area/Istex/Checkpoint">000106</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000106</idno><idno type="wicri:doubleKey">0105-2896:2015:Holyoake T:do:we:need</idno><idno type="wicri:Area/Main/Merge">000F62</idno><idno type="wicri:Area/Main/Curation">000F61</idno><idno type="wicri:Area/Main/Exploration">000F61</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Do we need more drugs for chronic myeloid leukemia?</title><author><name sortKey="Holyoake, Tessa L" sort="Holyoake, Tessa L" uniqKey="Holyoake T" first="Tessa L." last="Holyoake">Tessa L. Holyoake</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow</wicri:regionArea><orgName type="university">Université de Glasgow</orgName><placeName><settlement type="city">Glasgow</settlement><region type="country">Écosse</region></placeName></affiliation><affiliation></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Royaume-Uni</country></affiliation></author><author><name sortKey="Helgason, G Vignir" sort="Helgason, G Vignir" uniqKey="Helgason G" first="G. Vignir" last="Helgason">G. Vignir Helgason</name><affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow</wicri:regionArea><orgName type="university">Université de Glasgow</orgName><placeName><settlement type="city">Glasgow</settlement><region type="country">Écosse</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Immunological Reviews</title><title level="j" type="sub">Hematologic Malignancies</title><title level="j" type="alt">IMMUNOLOGICAL REVIEWS</title><idno type="ISSN">0105-2896</idno><idno type="eISSN">1600-065X</idno><imprint><biblScope unit="vol">263</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="106">106</biblScope><biblScope unit="page" to="123">123</biblScope><biblScope unit="page-count">18</biblScope><date type="published" when="2015-01">2015-01</date></imprint><idno type="ISSN">0105-2896</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0105-2896</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">The introduction of protein tyrosine kinase inhibitors (TKIs) in 1998 transformed the management of chronic myeloid leukemia (CML), leading to significantly reduced mortality and improved 5 year survival rates. However, the CML community is faced with several clinical issues that need to be addressed. Ten to 15% of CML patients are diagnosed in advanced phase, and small numbers of chronic phase (CP) cases experience disease progression each year during treatment. For these patients, TKIs induce only transient responses and alternative treatment strategies are urgently required. Depending on choice of first line TKI, approximately 30% of CML CP cases show suboptimal responses, due to a combination of poor compliance, drug intolerance, and drug resistance, with approximately 50% of TKI‐resistance caused by kinase domain mutations and the remainder due to unknown mechanisms. Finally, the chance of successful treatment discontinuation is on the order of only 10–20% related to disease persistence. Disease persistence is a poorly understood phenomenon; all CML patients have functional Philadelphia positive (Ph+) stem and progenitor cells in their bone marrows and continue to express BCR‐ABL1 by DNA PCR, even when in very deep remission and following treatment discontinuation. What controls the maintenance of these persisting cells, whether it is necessary to fully eradicate the malignant clone to achieve cure, and how that might be approached therapeutically are open questions.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Écosse</li></region><settlement><li>Glasgow</li></settlement><orgName><li>Université de Glasgow</li></orgName></list><tree><country name="Royaume-Uni"><region name="Écosse"><name sortKey="Holyoake, Tessa L" sort="Holyoake, Tessa L" uniqKey="Holyoake T" first="Tessa L." last="Holyoake">Tessa L. Holyoake</name></region><name sortKey="Helgason, G Vignir" sort="Helgason, G Vignir" uniqKey="Helgason G" first="G. Vignir" last="Helgason">G. Vignir Helgason</name><name sortKey="Holyoake, Tessa L" sort="Holyoake, Tessa L" uniqKey="Holyoake T" first="Tessa L." last="Holyoake">Tessa L. Holyoake</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F61 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F61 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:8FBAE5AFBB10757C28A4B796A960B9E16477F9E4
|texte= Do we need more drugs for chronic myeloid leukemia?
}}
| This area was generated with Dilib version V0.6.33. |  |